Lv2
150 积分 2023-12-26 加入
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium
6天前
已完结
Resolving Loss of Response to Ustekinumab in Crohn’s Disease: POWER Through or Switch Treatment?
6天前
已关闭
Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease
6天前
已完结
Letter: ustekinumab for the treatment of post‐surgical and refractory Crohn's disease
6天前
已完结
Predictive factors of the clinical efficacy of ustekinumab in patients with refractory Crohn’s disease: tertiary centers experience in Japan
6天前
已完结
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long‐term extension period of STARDUST
6天前
已完结
Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn’s Disease: 2025 AGA Evidence Synthesis
6天前
已完结
Re-induction With Intravenous Ustekinumab in Patients With Crohn’s Disease and a Loss of Response to This Therapy
6天前
已完结
Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn’s Disease
6天前
已完结
Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study
6天前
已完结
皖公网安备34019202002308
